News
Benefit of Empagliflozin in Patients with Chronic Kidney Disease – Results of the EMPA-KIDNEY Study
The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type 2 diabetes mellitus (T2DM) and chronic heart failure regardless of ejection fraction value. Its impact on renal function and the prognosis of patients with chronic kidney disease (CKD) irrespective of the presence of T2DM was specifically evaluated in the double-blind placebo-controlled EMPA-KIDNEY study.
Cardio-Renal-Metabolic Syndrome?
The association between type 2 diabetes (DM2) and atherosclerotic cardiovascular disease (ASCVD) is…
The Latest Updates of ESC Recommendations for Heart Failure Treatment
What is new in heart failure therapy? At the annual congress of the European Society of Cardiology…
Experience with Proton Radiotherapy for Anal Canal Carcinoma in Real Czech Practice
Radiotherapy has the potential to achieve complete tumor regression in patients with anal…
Facilitated Immunoglobulin Substitution Therapy in Paediatric Patients with Immunodeficiency – Real-World Data
Patients with humoral immunodeficiency are indicated for immunoglobulin substitution therapy. The…
Incidence of Osteoporosis in Patients with Atrial Fibrillation Treated with Different Oral Anticoagulants
Previous research has suggested an increased risk of osteoporosis and osteoporotic fractures in…
Results of Levothyroxine Treatment in Pregnant Women with Recurrent Pregnancy Losses with Subclinical Hypothyroidism or Anti-TPO Antibody Positivity
A recent meta-analysis of 15 studies involving a total of 1911 women with a history of recurrent…
Nirmatrelvir/ritonavir reduces the risk of hospitalization for COVID-19 even in the era of predominant omicron subvariants BA.4 and BA.5
One of the first studies to evaluate the efficacy of nirmatrelvir/ritonavir in non-hospitalized…
Effectiveness of the Sonicare For Kids Toothbrush in Preschool Children
A comparative study conducted as part of a graduation thesis in the field of Certified Dental…
Benefit of Adding Panitumumab to Maintenance Therapy in mCRC with Non-mutated RAS Oncogene
PANAMA was the first randomized study evaluating the addition of an anti-EGFR antibody to…